Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26347434 | 0.84 | ITGB3 (0.53) | TYRITGB3ITGA2BNPC1RAB9A | |
| SCHEMBL22193675 | 0.80 | ALDH1A1 (0.41) | — | |
| SCHEMBL22193744 | 0.80 | P4HB (0.32) | BCL2ITGB3ITGA2BNPC1RAB9A | |
| SCHEMBL22193977 | 0.79 | SLC5A2 (0.38) | BCL2HDAC8CTSSCTSKSLC5A1 | |
| SCHEMBL20635533 | 0.78 | ITGB3 (0.45) | BCL2HDAC8ITGB3ITGA2BCTSS | |
| SCHEMBL20634548 | 0.77 | SLC5A2 (0.45) | BCL2SLC5A1SLC5A2 | |
| SCHEMBL24109362 | 0.77 | ACE (0.45) | BCL2ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL24120462 | 0.74 | SLC5A2 (0.43) | BCL2NPC1RAB9ASLC5A1SLC5A2 | |
| SCHEMBL24120438 | 0.73 | PTPN1 (0.40) | BCL2HDAC8ITGB3ITGA2BSLC5A1 | |
| SCHEMBL22193920 | 0.73 | PTPN1 (0.40) | BCL2HDAC8ITGB3ITGA2BSLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220118104-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2022-04-21 | — | — | US | disclosed |
| WO-2020141459-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118104-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | TYR 787/4885BCL2 975/4885HDAC8 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.